LUTRONIC ANNOUNCES THE NEXT GENERATION ECO2, THE FASTEST CO2 FRACTIONAL LASER, IS NOW AVAILABLE
Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced today the availability of the next generation eCO2, the fastest CO2 fractional laser. It is premiering at AAD from March 18-23 in San Francisco along with the full compliment devices on display in the Lutronic booth #2512. "We are pleased release our fastest system yet; The eCO2 provides patients with faster treatments than competitors, while still maintaining the consistent fluency needed for efficacious results," says Rich Cohen, Global Clinical Science Officer at Lutronic.
eCO2 is best known for its ability to quickly treat deep ablative indications such as resurfacing and coagulation of soft tissue, scars, textural irregularities, fine lines, pigmented lesions, vascular dyschromia, and rhytides. The easy to use eCO2 has several patented features that offer customizable treatments, which help to minimize pain and lessen thermal damage, thus minimizing downtimes. Improving upon the workhorse eCO2 system, this next generation fractional CO2 laser further maximizes its speed and comfort by delivering its high fluence, small 120 µm spot size via the new larger scan sizes up to 18mm squared.
Dr. Jill Waibel, Medical Director and Owner of Miami Dermatology and Laser Institute in Miami, Florida, states that "eCO2 is a CO2 laser that can really make a difference in treating scars and for the prevention of early scar formation. What really got me excited about the eCO2 is the 120 micron spot size that allows me treat as deep, which when combined with dynamic mode I am able to quickly and efficiently treat large areas, which can take hours with other devices; in head to head comparisons with other CO2 devices the eCO2 is always faster."
Of particular interest to users is the ability to combine two operational modes in one delivery system, which is important when deep penetration and greater patient comfort is required. With both Static and Dynamic operation modes, users have the capability to stamp up to a 18x18mm scan area as well as the option to "air brush" the treatment area to reduce the "checkerboard" appearance that is common with currently available fractional CO2 devices.
With several international and U.S. patents, the eCO2 has multifunctional features, including an intuitive software that can select between a typical sequential beam pattern and a pseudo-random pattern called Controlled Chaos Technology, which minimizes the thermal damage from the laser. A wide range of indications may be treated with its 2 different treatment tip sizes (120 and 300 µm), including a point beam tip for traditional CO2 excision and vaporization of tissue-tags and pigmented lesions and optional surgical handpiece.
Dr. Jill Waibel will present on eCO2 during the AAD at a special dinner Symposium hosted by Lutronic which will be held on Saturday March 21st beginning at 7pm. The symposium will also feature Dr. Gilly Munavalli, medical director and founder of Dermatology Laser and Vein Specialists of the Carolinas; will share his experience with Infini, a High Intensity Focused RF, and Spectra’s new Gold Handpiece for treating Post acne erythema. Dr. Christine Dierickx, Owner of Skimperium, Belgium, will also share her vast experience with Lutronic devices.
Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established over 17 years ago to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple setting and treatment options for customized treatments, which optimize outcomes for a wide variety of conditions and treatments including melasma, tattoo removal, soft tissue incision, vascular lesions, hair removal, wrinkle reduction, skin resurfacing, body/facial contouring, chronic pain and more.
With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today’s market. Devoting more than 15% of revenues to R&D, Lutronic holds more than 130 current and pending patents worldwide. With more than 250 employees worldwide, Lutronic has offices in the US, Korea, China, Japan, and Europe, a worldwide network of distributors, and is ever expanding.
For more information about Lutronic and its products, please visit: www.lutronic.com